Selisistat ( DrugBank: Selisistat )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 3 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-001131-23-GB (EUCTR) | 24/10/2011 | 18/07/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A | Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | Siena Biotech SpA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;Italy;United Kingdom | |||
| 2 | EUCTR2011-001131-23-IT (EUCTR) | 20/10/2011 | 22/11/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 | Huntington's disease MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | SIENA BIOTECH SPA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;United Kingdom;Italy | |||
| 3 | EUCTR2011-001131-23-DE (EUCTR) | 21/09/2011 | 27/06/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A | Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | Siena Biotech SpA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;Italy;United Kingdom |